Across TCGA pan-cancer cohorts, APOA2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated APOA2 data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher APOA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated APOA2 expression acts as an unfavorable survival marker.
LGG and ACC are the cancer types where APOA2 Mutation most reproducibly stratifies survival.